StemRIM

Tokyo Stock Exchange 4599.T

StemRIM Operating Cash Flow for the year ending July 31, 2024: USD -12.55 M

StemRIM Operating Cash Flow is USD -12.55 M for the year ending July 31, 2024, a -257.31% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

StemRIM Operating Cash Flow for the year ending July 31, 2023 was USD 7.98 M, a 175.69% change year over year.
StemRIM Operating Cash Flow for the year ending July 31, 2022 was USD -10.54 M, a -122.52% change year over year.
StemRIM Operating Cash Flow for the year ending July 31, 2021 was USD -4.74 M, a -187.22% change year over year.
StemRIM Operating Cash Flow for the year ending July 31, 2020 was USD 5.43 M, a 175.98% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

Tokyo Stock Exchange: 4599.T

StemRIM

CEO	Mr. Masatsune Okajima
IPO Date	Aug. 9, 2019
Location	Japan
Headquarters	Saito Bio-Incubator
Employees	45
Sector	Healthcare
Industries Biotechnology

Description

StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. It develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy; PJ2, a regeneration-inducing medicine novel peptides A and B; PJ3, a biologic regeneration-inducing protein; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.

Key trends

Past 5 years